四神丸治疗肠易激综合征疗效与安全性的Meta分析及试验序贯分析
本研究通过Meta分析和试验序贯分析评估四神丸治疗腹泻型肠易激综合征(IBS-D)的疗效与安全性,纳入34项随机对照试验共2976例受试者。结果显示,四神丸单用或联合西药可显著提高治疗有效率、改善整体症状评分及腹痛、腹泻、腹胀、食欲不振等单项症状,并降低复发率;联合艾灸亦进一步改善疗效。安全性分析未报告严重不良事件,试验序贯分析证实主要结局样本量充足,但原始研究质量存在局限。
要点
- 四神丸单用或联合西药可显著提高IBS-D治疗有效率并改善腹痛腹泻等症状。
- 四神丸可显著降低IBS-D复发率,且联合艾灸可进一步改善疗效。
- 安全性分析未报告严重不良事件,但原始研究存在样本量小、随访短等局限。
核心结论
- 四神丸单用或联合艾灸可有效缓解IBS-D症状并降低复发率,是潜在有益干预措施。
- 现有研究整体质量存在局限,包括样本量较小、随访时间不够长及缺乏双盲设计。
研究设计与样本
- 系统检索7个数据库自建库至2024年10月31日的随机对照试验,最终纳入34项RCT共2976例受试者。
- 采用随机效应或固定效应模型进行Meta分析,并应用试验序贯分析估计样本量及验证稳健性。
主要发现
- 四神丸单用(RR=1.28;95%CI:1.21,1.34;P<0.00001)或联合西药(RR=1.26;95%CI:1.18,1.35;P<0.00001)较单用西药显著提高治疗有效率。
- 四神丸降低整体症状评分(SMD=-1.06;95%CI:-1.50,-0.61;Z=4.66;P<0.00001),并改善腹痛(MD=-0.66;95%CI:-0.76,-0.56;Z=12.99;P<0.00001)、腹泻(MD=-0.69;95%CI:-0.81,-0.56;Z=10.82;P<0.00001)、腹胀(MD=-0.65;95%CI:-1.06,-0.24;Z=3.13;P=0.002)及食欲不振(MD=-0.55;95%CI:-0.66,-0.44;Z=9.80;P<0.00001)。
- 四神丸显著降低复发率(RR=0.40;95%CI:0.29,0.55;P<0.00001)。
- 四神丸联合艾灸进一步改善治疗结局(RR=1.22;95%CI:1.08,1.37;P=0.0001),并改善腹痛(MD=-0.42;95%CI:-0.81,-0.04;Z=2.17;P=0.03)、腹泻(MD=-0.41;95%CI:-0.64,-0.17;Z=3.41;P=0.0006)、腹胀(MD=-0.40;95%CI:-0.69,-0.11;Z=2.67;P=0.008)及食欲不振(MD=-0.30;95%CI:-0.49,-0.10;Z=2.93;P=0.003)。
- 安全性分析显示四神丸及四神丸联合艾灸安全性较高,所有纳入试验均未报告严重不良事件;试验序贯分析证实主要结局样本量充足。
关键数值与推荐
- 四神丸单用对比西药治疗IBS-D的有效率RR=1.28(95%CI:1.21,1.34;P<0.00001)。
- 四神丸联合西药对比单用西药的有效率RR=1.26(95%CI:1.18,1.35;P<0.00001)。
- 四神丸降低复发率的RR=0.40(95%CI:0.29,0.55;P<0.00001)。
- 四神丸联合艾灸对比对照的疗效RR=1.22(95%CI:1.08,1.37;P=0.0001)。
临床怎么用
- 对于IBS-D患者,可考虑单独使用四神丸或联合西药以改善治疗有效率及腹痛、腹泻、腹胀、食欲不振等症状。
- 四神丸联合艾灸可作为内外合治的中医干预方案,进一步改善症状及治疗结局。
- 四神丸在降低复发率方面具有优势,可用于减少IBS-D复发。
局限性
- 纳入研究整体质量存在局限,包括样本量相对较小、随访时间不够长及缺乏双盲设计。
- 未来需开展高质量、长期、随机双盲临床试验以提升研究结果的可靠性与外部适用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders (FGIDs), characterized by complex pathogenesis, prolonged disease duration, frequent recurrence, and a significant impact on patients' quality of life. Si-Shen-Wan (SSW), a renowned traditional Chinese medicine formula, is widely recognized for its efficacy in managing gastrointestinal symptoms, particularly diarrhea, and is commonly used to treat diarrhea-predominant IBS (IBS-D). This study utilized a meta-analysis to evaluate the efficacy and safety of SSW in the treatment of IBS-D. METHODS: A comprehensive search for randomized controlled trials (RCTs) was conducted across seven databases from their inception to 31 October 2024. The analysis included outcomes such as efficacy rate, overall symptom score, abdominal pain score, diarrhea score, abdominal distension score, loss of appetite score, recurrence rate, and adverse events. Meta-analyses were performed using either a random-effects or fixed-effects model. Trial sequential analysis (TSA) was applied to estimate the sample size and validate the robustness of the meta-analysis. RESULTS: A total of 34 RCTs involving 2,976 participants met the inclusion criteria. The findings demonstrated that SSW alone (RR = 1.28; 95% CI: 1.21, 1.34; P < 0.00001) or combined with biomedicine (RR = 1.26; 95% CI: 1.18, 1.35; P < 0.00001) significantly improved treatment efficacy compared to biomedicine alone. SSW also reduced the overall symptom score (SMD = -1.06; 95% CI: -1.50, -0.61; Z = 4.66; P < 0.00001) and alleviated key symptoms, including abdominal pain (MD = -0.66; 95% CI: -0.76, -0.56; Z = 12.99; P < 0.00001), diarrhea (MD = -0.69; 95% CI: -0.81, -0.56; Z = 10.82; P < 0.00001), abdominal distension (MD = -0.65; 95% CI: -1.06, -0.24; Z = 3.13; P = 0.002), and loss of appetite (MD = -0.55; 95% CI: -0.66, -0.44; Z = 9.80; P < 0.00001). The recurrence rate was also significantly reduced (RR = 0.40; 95% CI: 0.29, 0.55; P < 0.00001). Additionally, SSW combined with moxibustion-a traditional Chinese medicine therapy integrating internal and external treatments-also further improved treatment outcomes (RR = 1.22; 95% CI: 1.08, 1.37; P = 0.0001). This combination effectively reduced abdominal pain (MD = -0.42; 95% CI: -0.81, -0.04; Z = 2.17; P = 0.03), diarrhea (MD = -0.41; 95% CI: -0.64, -0.17; Z = 3.41; P = 0.0006), abdominal distension (MD = -0.40; 95% CI: -0.69, -0.11; Z = 2.67; P = 0.008), and loss of appetite (MD = -0.30; 95% CI: -0.49, -0.10; Z = 2.93; P = 0.003). Safety analysis revealed a high level of safety for SSW and SSW combined with moxibustion, with no serious adverse events reported in any of the included trials. TSA confirmed an adequate sample size for the primary outcome, supporting the efficacy of SSW in IBS-D treatment. CONCLUSION: SSW, either used alone or combined with moxibustion, is effective in alleviating IBS-D symptoms and reducing recurrence rates, making it a potentially beneficial intervention. However, certain limitations remain in the overall quality of the current studies, including relatively small sample sizes, insufficiently long follow-up periods, and the absence of a double-blind design. Future research should emphasize the design and implementation of high-quality, long-term, randomized, double-blind clinical trials to further enhance the reliability and external applicability of the research findings. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=597979, identifier CRD42024597979.
引用
- Liu Q, Shi Z, Jiang Y, et al. Efficacy and safety of Chinese botanical drug Si Shen Wan in irritable bowel syndrome: a meta-analysis and trial sequential analysis of randomized controlled trials. Front Pharmacol. 2025. PMID: 40529486. doi:10.3389/fphar.2025.1534904
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。